Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Staying well after depression: trial design and protocol | Williams et al. BMC Psychiatry 2010 10 23 http 1471-244X 10 23 BMC Psychiatry STUDY PROTOCOL Open Access Staying well after depression trial design and protocol 1 2 3 s . I z- 1 3 3 1 J Mark G Williams Ian T Russell Catherine Crane Daphne Russell Chris J Whitaker Danielle S Duggan Thorsten Barnhofer1 Melanie JV Fennell1 Rebecca Crane4 Sarah Silverton4 Abstract Background Depression is often a chronic relapsing condition with relapse rates of 50-80 in those who have been depressed before. This is particularly problematic for those who become suicidal when depressed since habitual recurrence of suicidal thoughts increases likelihood of further acute suicidal episodes. Therefore the question how to prevent relapse is of particular urgency in this group. Methods Design This trial compares Mindfulness-Based Cognitive Therapy MBCT a novel form of treatment combining mindfulness meditation and cognitive therapy for depression with both Cognitive Psycho-Education CPE an equally plausible cognitive treatment but without meditation and treatment as usual TAU . It will test whether MBCT reduces the risk of relapse in recurrently depressed patients and the incidence of suicidal symptoms in those with a history of suicidality who do relapse. It recruits participants screens them by telephone for main inclusion and exclusion criteria and if they are eligible invites them to a pre-treatment session to assess eligibility in more detail. This trial allocates eligible participants at random between MBCT and TAU CPE and TAU and TAU alone in a ratio of 2 2 1 stratified by presence of suicidal ideation or behaviour and current anti-depressant use. We aim to recruit sufficient participants to allow for retention of 300 following attrition. We deliver both active treatments in groups meeting for two hours every week for eight weeks. We shall estimate effects on rates of relapse and suicidal symptoms over 12 months following treatment and assess clinical status .